Indoleamine 2,3 dioxygenase (IDO1), the rate-limiting enzyme of the kynurenine pathway, and programmed cell death 1 ligand 1 (PD-L1) are potential immunotherapeutic targets against soft tissue sarcoma. Here, IDO1 is linked to soft tissue sarcoma.